Simvastatin in Secondary Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

September 13, 2022

Study Completion Date

June 15, 2023

Conditions
Secondary Progressive Multiple Sclerosis
Interventions
DRUG

Simvastatin

Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks

Trial Locations (1)

WC1B 5EH

Department of Neuroinflammation, UCL Institute of Neurology, London

All Listed Sponsors
collaborator

National Multiple Sclerosis Society

OTHER

lead

University College, London

OTHER

NCT03896217 - Simvastatin in Secondary Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter